Immuno-Oncology

Toward more predictive preclinical tumor mouse models: conventional tumor models with immunodeficient animals only monitor the effect of a drug on the tumor itself. The approval in 2011 of the first immune-checkpoint inhibitor (Nobel price winner in 2018) has validated the immuno-oncology therapeutic approach against many forms of cancer. The reconstitution of the full functional human immune system in immune-deficient triple KO mice such as NOG/NCG/NSG/BRG provides a unique opportunity to assess the efficacy of new drug candidates acting on both human immune cells such as T cells, myeloid cells and NK cells, and on the tumor itself (bi-specific mAb, ADCC mediation, …) with either Solid (Melanoma, breast, ovarian,…) or Liquid (T-cell lymphoma, B-cell Lymphoma, AML)  tumors.

 

DATA Driven with more than 98 studies completed

Immune Check Point Inhibitor

  • Hu-NOG engrafted with Gastric Tumor Cells
  • Treatment with Anti-PD1
  • Combo Therapy tested in the same setting

Bi-Specific Ab with ADCC activity

  • Hu-NOG engrafted with HCT-116 colorectal cancer cells
  • Treatment with Bi-specific Ab
  • ADCC activity

T Cell Immunity – Vaccination

  • Hu-NOG vaccinated against Mart-1 peptide
  • Cellular response in the peripheral blood 28 days after vaccination
  • Tetramer Staining of CD8+ cells

Immune Cell Infiltration – IHC

  • Hu-NOG engrafted with Gastric tumor cells
  • Immune infiltration (CD8 staining)

Immune Cell Infiltration – Flow Cytometry

  • Automated mechanic and enzymatic digestion of human tumors
  • Flow Cytometry analysis on whole tumor

Combination Therapies

Click here to change this text

Strength of TransCure bioServices in cancer/immuno-Oncology/PDX

  • >2’000 hu-mouse tested for cancer/immuno-oncology/PDX
  • Validated models for: Immune Checkpoint Inhibitors, PDX, Oncolytic Viruses, ADCC, Vaccines
  • Ideal for Combination Strategy
  • Expertise in Protocol/Study Design/Endpoints with hu-mouse
  • Quality Raw Data Collection and Report Analysis
  • Time and Cost-Saving, Competitive FTE rate

 

Find out more information about our fee-for-services: HIV, Inflammation/IBD

 


Share this!